

Kathleen V Fitch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2653731/publications.pdf>

Version: 2024-02-01

38
papers

1,562
citations

430874

18
h-index

330143

37
g-index

38
all docs

38
docs citations

38
times ranked

2041
citing authors

#	ARTICLE	IF	CITATIONS
1	Sustainable food systems and nutrition in the 21st century: a report from the 22nd annual Harvard Nutrition Obesity Symposium. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 18-33.	4.7	43
2	COVID-19 Vaccination Rates in a Global HIV Cohort. <i>Journal of Infectious Diseases</i> , 2022, 225, 603-607.	4.0	8
3	Prevalence and Correlates of Electrocardiographic Abnormalities in Adults With HIV: Insights From the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 349-359.	2.1	4
4	Proteomic Signature of Subclinical Coronary Artery Disease in People With HIV: Analysis of the REPRIEVE Mechanistic Substudy. <i>Journal of Infectious Diseases</i> , 2022, 226, 1809-1822.	4.0	11
5	Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention. <i>JAMA Network Open</i> , 2021, 4, e2114923.	5.9	38
6	Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, 2009-2022.	5.8	19
7	Altered pattern of circulating miRNAs in HIV lipodystrophy perturbs key adipose differentiation and inflammation pathways. <i>JCI Insight</i> , 2021, 6, .	5.0	10
8	Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab537.	0.9	19
9	Anti-Inflammatory Interleukin 10 Inversely Relates to Coronary Atherosclerosis in Persons With Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2020, 221, 510-515.	4.0	15
10	An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2020, 222, S41-S51.	4.0	1
11	Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum. <i>Journal of Infectious Diseases</i> , 2020, 222, S31-S40.	4.0	4
12	Measures of Adipose Tissue Redistribution and Atherosclerotic Coronary Plaque in HIV. <i>Obesity</i> , 2020, 28, 749-755.	3.0	9
13	Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics Approach. <i>Journal of Infectious Diseases</i> , 2020, 222, 929-939.	4.0	16
14	Relationship of Telomere Length to Fat Redistribution in HIV. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa523.	0.9	3
15	Comparison of visceral fat measurement by dual-energy X-ray absorptiometry to computed tomography in HIV and non-HIV. <i>Nutrition and Diabetes</i> , 2019, 9, 6.	3.2	13
16	Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers. <i>American Heart Journal</i> , 2019, 212, 1-12.	2.7	43
17	Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). <i>American Heart Journal</i> , 2019, 212, 23-35.	2.7	99
18	Relationship of visceral and subcutaneous adipose depots to markers of arterial injury and inflammation among individuals with HIV. <i>Aids</i> , 2019, 33, 229-236.	2.2	18

#	ARTICLE	IF	CITATIONS
19	SUN-052 Low Vitamin D Is Associated with Coronary Atherosclerosis in Women with HIV. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0
20	Brief Report: Statin Effects on Myocardial Fibrosis Markers in People Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 78, 105-110.	2.1	14
21	Sex Differences in Subclinical Coronary Atherosclerotic Plaque Among Individuals With HIV on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 78, 421-428.	2.1	18
22	I-FABP Is Higher in People With Chronic HIV Than Elite Controllers, Related to Sugar and Fatty Acid Intake and Inversely Related to Body Fat in People With HIV. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy288.	0.9	25
23	Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial. <i>EBioMedicine</i> , 2018, 35, 58-66.	6.1	16
24	Dysfunctional Subcutaneous Fat With Reduced Dicer and Brown Adipose Tissue Gene Expression in HIV-Infected Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1225-1234.	3.6	39
25	Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , 2015, 2, e52-e63.	4.7	188
26	RAAS Activation Is Associated With Visceral Adiposity and Insulin Resistance Among HIV-infected Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2873-2882.	3.6	75
27	HIV-Related Cardiovascular Disease, Statins, and the REPRIEVE Trial. <i>Topics in Antiviral Medicine</i> , 2015, 23, 146-9.	0.1	70
28	Soluble CD163 Is Associated With Shortened Telomere Length in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 67, 414-418.	2.1	26
29	Effects of aging and smoking on carotid intima-media thickness in HIV-infection. <i>Aids</i> , 2013, 27, 49-57.	2.2	26
30	Noncalcified Coronary Atherosclerotic Plaque and Immune Activation in HIV-Infected Women. <i>Journal of Infectious Diseases</i> , 2013, 208, 1737-1746.	4.0	185
31	Deiodinase 2 Expression Is Increased in Dorsocervical Fat of Patients with HIV-Associated Lipohypertrophy Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E602-E607.	3.6	29
32	Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. <i>Aids</i> , 2012, 26, 587-597.	2.2	73
33	Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. <i>Aids</i> , 2012, 26, 2409-2412.	2.2	177
34	Nutritional and metabolic correlates of cardiovascular and bone disease in HIV-infected patients. <i>American Journal of Clinical Nutrition</i> , 2011, 94, 1721S-1728S.	4.7	16
35	Increased Coronary Artery Calcium Score and Noncalcified Plaque Among HIV-Infected Men: Relationship to Metabolic Syndrome and Cardiac Risk Parameters. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 55, 495-499.	2.1	45
36	Decreased respiratory quotient in relation to resting energy expenditure in HIV-infected and noninfected subjects. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 608-615.	3.4	13

#	ARTICLE	IF	CITATIONS
37	Relation of Body Composition to Body Mass Index in HIV-Infected Patients With Metabolic Abnormalities. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 47, 174-184.	2.1	56
38	Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. <i>Aids</i> , 2006, 20, 1843-1850.	2.2	98